PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer

Zhao, Senxia; Li, Yibin; Li, Gang; Ye, Juanping; Wang, Rong; Zhang, Xiaoting; Li, Fei; Gao, Chang; Li, Junbiao; Jiang, Jie; Mi, Yanjun

doi:10.1016/j.ejphar.2023.176004

Cited by 1 publication

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multimodal therapies have been observed to stratify risk, have stronger chemotherapy, and multimodality treatment strategies have significantly improved the mortality for children with cancer. Initial in vitro results showed additive and synergistic effects with other cell cycle inhibitors indirectly, or directly in the CDC25-specific inhibition paradigm that proved promising in their anti-proliferative action on various cancer cell lines (Larsson et al, 2009;Ock and Kim, 2021;Zhao et al, 2023). However, more improvement in survival rates and a decrease in long-term negative effects are required (Forrest et al, 2018).…”

Section: Exploring Combination Therapies Involving Cdc25 Inhibitorsmentioning

confidence: 99%

Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine

Dakilah,

Harb,

Abu-Gharbieh

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

The global burden of cancer continues to rise, underscoring the urgency of developing more effective and precisely targeted therapies. This comprehensive review explores the confluence of precision medicine and CDC25 phosphatases in the context of cancer research. Precision medicine, alternatively referred to as customized medicine, aims to customize medical interventions by taking into account the genetic, genomic, and epigenetic characteristics of individual patients. The identification of particular genetic and molecular drivers driving cancer helps both diagnostic accuracy and treatment selection. Precision medicine utilizes sophisticated technology such as genome sequencing and bioinformatics to elucidate genetic differences that underlie the proliferation of cancer cells, hence facilitating the development of customized therapeutic interventions. CDC25 phosphatases, which play a crucial role in governing the progression of the cell cycle, have garnered significant attention as potential targets for cancer treatment. The dysregulation of CDC25 is a characteristic feature observed in various types of malignancies, hence classifying them as proto-oncogenes. The proteins in question, which operate as phosphatases, play a role in the activation of Cyclin-dependent kinases (CDKs), so promoting the advancement of the cell cycle. CDC25 inhibitors demonstrate potential as therapeutic drugs for cancer treatment by specifically blocking the activity of CDKs and modulating the cell cycle in malignant cells. In brief, precision medicine presents a potentially fruitful option for augmenting cancer research, diagnosis, and treatment, with an emphasis on individualized care predicated upon patients’ genetic and molecular profiles. The review highlights the significance of CDC25 phosphatases in the advancement of cancer and identifies them as promising candidates for therapeutic intervention. This statement underscores the significance of doing thorough molecular profiling in order to uncover the complex molecular characteristics of cancer cells.

show abstract

Section: Exploring Combination Therapies Involving Cdc25 Inhibitorsmentioning

confidence: 99%

Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine

Dakilah,

Harb,

Abu-Gharbieh

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

PI3K/mTOR inhibitor VS-5584 combined with PLK1 inhibitor exhibits synergistic anti-cancer effects on non-small cell lung cancer

Cited by 1 publication

References 54 publications

Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine

Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine

Contact Info

Product

Resources

About